Introduction Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although CRC has historically been concentrated in Western high-income countries, its global epidemiology is rapidly changing, with rising incidence now extending across diverse geographic and socioeconomic settings.
Introduction
Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although CRC has historically been concentrated in Western high-income countries, its global epidemiology is rapidly changing, with rising incidence now extending across diverse geographic and socioeconomic settings.
Problem Statement
The global rise in CRC is increasingly driven by early-onset disease, particularly in individuals younger than 50 years, challenging traditional assumptions that CRC is predominantly a disease of older adults in high-income populations. This shift cannot be fully explained by inherited susceptibility or expanded screening alone, suggesting that evolving environmental, metabolic and lifestyle exposures are playing a major role in reshaping CRC risk worldwide.
Summary
This review highlights a major epidemiologic transition in CRC, with disease burden increasingly shifting beyond Western high-income countries and disproportionately affecting younger populations. The rise in early-onset CRC, first recognized in the 1990s, is now a global phenomenon and appears to reflect a birth-cohort effect implicating shared generational exposures rather than screening patterns alone. The authors emphasize that while hereditary risk remains important, emerging global CRC trends are more likely driven by non-genetic factors, including Westernized dietary patterns, sedentary lifestyle, obesity, gut microbial disruption and increasing exposure to environmental contaminants associated with rapid urbanization. These exposures may contribute not only to carcinogenesis but also to the distinct biology of early-onset CRC. The review further underscores the potential of integrating genomic, epigenomic and microbiome profiling to better define disease mechanisms and support earlier detection and precision prevention. Importantly, the authors highlight a major evidence gap in low- and middle-income regions, where under-representation in molecular and epidemiologic studies risks widening disparities in CRC prevention and control. This review positions early-onset CRC as a defining global oncology challenge requiring both biologic and public health recalibration.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.